|
|
View Clinical Trial (Medical Research Study)
|
Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone - NCT00522392-17822 (Clinical Trial 181587)
Permalink: http://www.ClinicalConnection.com/exp/ExpandedPatientViewStudy181587.aspx
|
** Please review additional "Nearby Studies" on right ----->
This is an archived study that is no longer available, if you
would like to find active studies please
search our studies.
|
|
 |
 |
|
| City: |
|
Danville |
|
State:
|
|
PA |
| Zip Code: |
|
17822 |
| Conditions: |
|
Multiple Myeloma and Plasma Cell Neoplasm |
| Purpose: |
|
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different
ways to stop the growth of cancer cells, either by killing the cells or by stopping them
from dividing. Lenalidomide may stimulate the immune system in different ways and stop
cancer cells from growing. It is not yet known whether giving bortezomib together with
dexamethasone is more effective with or without lenalidomide in treating multiple myeloma.
PURPOSE: This randomized phase III trial is studying bortezomib, dexamethasone, and
lenalidomide to see how well they work compared with bortezomib and dexamethasone in
treating patients with multiple myeloma previously treated with dexamethasone.
|
| Study summary: |
|
OBJECTIVES:
Primary
- To compare the progression-free survival (PFS) of patients with previously treated
symptomatic multiple myeloma treated with consolidation therapy comprising bortezomib
and dexamethasone with vs without lenalidomide.
Secondary
- To determine the incremental ability of these regimens in attaining a complete response
or a very good partial response (VGPR) in these patients.
- To compare the overall survival of patients treated with these regimens.
- To compare the toxicity of these regimens in these patients.
- To compare the quality of life of these patients.
- To examine the impact of differential treatment response, if observed, on quality of
life of these patients.
- To obtain prospective data on multiple myeloma specific quality of life attributes.
OUTLINE: Patients are stratified according to prior induction therapy with lenalidomide and
dexamethasone (yes vs no) and whether or not they are in complete response after induction
therapy at study registration (yes vs no). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive bortezomib IV on days 1, 4, 8, and 11, oral lenalidomide once a
day on days 1-14, and oral dexamethasone once a day on days 1-4. Treatment repeats
every 21 days for 8 courses in the absence of disease progression or unacceptable
toxicity.
- Arm II: Patients receive bortezomib IV on days 1, 4, 8, and 11 and oral dexamethasone
once a day on days 1-4. Treatment repeats every 21 days for 8 courses in the absence of
disease progression or unacceptable toxicity.
Quality of life is assessed periodically.
After completion of study treatment, patients are followed every 3 months for 2 years, every
6 months for 3 years, and then every 12 months for 5 years. |
| Criteria: |
|
DISEASE CHARACTERISTICS:
- Diagnosis of symptomatic multiple myeloma
- Must meet the following criteria at one point in the course of the disease for the
original diagnosis of myeloma:
- Bone marrow plasmacytosis with > 10% plasma cells or sheets of plasma cells or
biopsy proven plasmacytoma
- Must have symptomatic disease that prompted the initiation of therapy (e.g.,
anemia, hypercalcemia, bone disease, or renal dysfunction)
- Must have completed a minimum of 1 and a maximum of 6 courses of a
dexamethasone-based regimen within the past 8 weeks, including any of the following:
- Dexamethasone alone
- Vincristine, doxorubicin, and dexamethasone
- Thalidomide and dexamethasone
- Lenalidomide and dexamethasone
- Liposomal doxorubicin and dexamethasone
- The combination of any of the above agents and dexamethasone
- Cyclophosphamide, lenalidomide, and dexamethasone
- Received a minimum cumulative dose of 160 mg of dexamethasone (no maximum dose
specified)
- Must have not experienced progressive disease on the dexamethasone-based regimen
- Patients diagnosed with only smoldering myeloma or monoclonal gammopathy of
undetermined significance are not eligible
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Hemoglobin > 7 g/dL
- Platelet count > 75,000/mm^3
- Absolute neutrophil count > 1,000/mm^3 (without the use of growth factors to increase
ANC)
- Creatinine < 2.5 mg/dL
- Direct bilirubin < 1.5 mg/dL
- ALT and AST < 2.5 times upper limit of normal
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective double-method contraception for 4 weeks prior to,
during, and for 4 weeks after completion of study therapy
- No active uncontrolled seizure disorder
- No seizure within the past 6 months
- No concurrent uncontrolled illness that would limit compliance with the study,
including any of the following:
- Uncontrolled hypertension
- Symptomatic congestive heart failure
- Unstable angina
- Uncontrolled cardiac arrhythmia
- Uncontrolled psychiatric illness or social situation
- History of Steven Johnson syndrome
- No peripheral neuropathy ≥ grade 2
- No active uncontrolled infection
- Patients with a history of prior malignancy are eligible provided there is no active
malignancy AND there is a low expectation of recurrence within 6 months
- Must be willing and able to receive prophylaxis with aspirin (325 mg/day) or
alternative prophylaxis with low molecular weight heparin or coumadin
- Patients with prior DVT are eligible provided they remain on the anticoagulation
regimen that was prescribed for treatment of the DVT throughout study therapy
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- At least 14 days since prior palliative and/or localized radiotherapy
- Prior bortezomib allowed
- Concurrent bisphosphonates or growth factors (e.g., granulocyte and/or erythropoietic
agents) for multiple myeloma allowed |
|
|
|
|
|
|
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
November 2, 2009 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical trials are medical research studies designed to test the safety and/or
effectiveness of new drugs, devices, or treatments in humans. These studies are
conducted worldwide for a range of conditions and illnesses. Learn more about
clinical research and participating in a study at
About Clinical Trials.
|
|
|
|
|
|
|
|